Nivolumab

In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.

The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally advanced squamous cell carcinoma of the head and neck.

Satricabtagene autoleucel improved PFS compared with physician’s choice of therapy for patients with Claudin18.2 expression-positive advanced gastric or gastroesophageal junction cancers, according to the agent’s manufacturer.

The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is indicated, according to a press release.

In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the 2024 World Conference on Lung Cancer, as well as Healio’s top headlines from the meeting.

In this edition, FDA approves Rybrevant for advanced lung cancer, screening orders in eligible patients higher with digital health program and more.

Nivolumab plus chemotherapy significantly extended PFS for children and adults with newly diagnosed advanced Hodgkin lymphoma compared with standard of care, according to results of a randomized phase 3 trial.

The FDA expanded the approval of nivolumab for treatment of non-small cell lung cancer.

In this episode of Meeting Mic, we bring you pearls and perspectives from the 2024 World Conference on Lung Cancer, as well as Healio’s top headlines from the meeting.

In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab ‘may be a new standard’ and more.